GlassScriptPhysician profile
Charles A Smith
NPI 1538363239
$9,110.97
in general payments reported to CMS, 2019-2025
43 companies · $679 in 2025
The $679 reported for 2025 was more than what 82% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,319 · 2022: $2,478 · 2023: $2,030 · 2024: $1,606 · 2025: $679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,224 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,224.33 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,572.54 | 2021-2025 | |
| Amgen INC. | $707.85 | 2021-2023 | Kyprolis, Lumakras, Prolia |
| Incyte Corporation | $694.57 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| E.R. Squibb & Sons, L.L.C. | $535.71 | 2021-2025 | Opdivo, Opdualag |
| Lilly USA, LLC | $500.78 | 2021-2024 | Verzenio, Jaypirca, Retevmo |
| Regeneron Healthcare Solutions, INC. | $479.69 | 2021-2025 | Libtayo |
| Seagen INC. | $451.84 | 2021-2023 | Adcetris, Padcev, Tukysa |
| Janssen Biotech, INC. | $387.06 | 2021-2025 | Darzalex, Erleada, Rybrevant |
| Sobi, INC | $384.71 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $370.49 | 2021-2025 | Calquence, Lynparza, Imfinzi |
| Glaxosmithkline, LLC. | $313.30 | 2021-2024 | Ojjaara, Jemperli, Shingrix |
| Abbvie INC. | $251.44 | 2023-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $242.45 | 2021-2023 | Imbruvica, Epkinly |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.92 | 2021-2024 | Gilotrif |
| Genzyme Corporation | $202.42 | 2021-2022 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $183.83 | 2022-2023 | |
| Pharmaessentia USA Corporation | $126.60 | 2023-2025 | Besremi |
| Astellas Pharma US INC | $109.86 | 2021-2025 | Xtandi |
| Sumitomo Pharma America, INC. | $105.67 | 2023-2024 | Orgovyx |
| Celgene Corporation | $102.00 | 2021-2023 | Reblozyl |
| Blueprint Medicines Corporation | $92.71 | 2022-2023 | Ayvakit |
| Genentech USA, INC. | $89.76 | 2023-2025 | Tecentriq, Polivy, Lunsumio |
| Merck Sharp & Dohme LLC | $88.40 | 2021-2024 | Keytruda |
| Adc Therapeutics America, INC. | $76.35 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.10 | 2023-2024 | Fruzaqla |
| Daiichi Sankyo INC. | $70.97 | 2024-2025 | Enhertu |
| Aveo Pharmaceuticals, INC. | $60.99 | 2022 | |
| Rigel Pharmaceuticals, INC. | $58.82 | 2022-2023 | Tavalisse, Rezlidhia |
| Myriad Genetic Laboratories, INC. | $58.39 | 2022-2024 | Precisetumor |
| Alexion Pharmaceuticals, INC. | $56.14 | 2022 | |
| Acrotech Biopharma INC. | $55.05 | 2021-2023 | Beleodaq |
| Tersera Therapeutics LLC | $50.77 | 2023-2025 | Zoladex, Xermelo |
| Genmab U.S., INC. | $42.57 | 2023 | Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $40.51 | 2021-2022 | |
| Kyowa Kirin, INC. | $40.50 | 2021-2024 | Poteligeo |
| Atricure, INC. | $40.36 | 2024 | |
| Kite Pharma, INC. | $39.70 | 2025 | Yescarta |
| Eisai INC. | $35.95 | 2021-2024 | |
| Coherus Oncology, INC. | $24.32 | 2024 | |
| Deciphera Pharmaceuticals INC. | $23.53 | 2021 | |
| Pharmacosmos Therapeutics INC. | $17.25 | 2023 | Monoferric |
| Sun Pharmaceutical Industries INC. | $14.97 | 2023 | Odomzo, Yonsa |
| Stemline Therapeutics INC. | $14.13 | 2023 | Orserdu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.